Cortex Terminal
Decision infrastructure in action. Daily briefings, entity watchlists, social intelligence monitoring, and hallucination containment — the intelligence layer your organization is missing.
March 31, 2026
Generated 06:00 UTC
Today's Briefing
Executive Summary: FDA issues updated guidance on AI-assisted drug labeling. Novo Nordisk announces Phase III results for next-gen GLP-1. Senate hearing on biosimilar pricing scheduled for April 8. Overall confidence: 92%.
Key Developments
FDA CDER issues draft guidance on AI-generated labeling claims for biologics
Regulatory Filing
Confirmed
Novo Nordisk Phase III trial for CagriSema shows 22.7% weight loss at 68 weeks
Clinical Trial Data
Confirmed
Senate HELP Committee to hold hearing on biosimilar interchangeability standards
Legislative
Inferred
Anomalies Detected
• Unusual spike in Eli Lilly GLP-1 mentions on social media (3.2x baseline)
• Patent filing activity for biosimilar manufacturing on March 27
Risk Alerts
⚠️ Moderate: Competitive pressure from new GLP-1 entrant increasing
⚠️ Low: Regulatory timeline risk for FDA CDER decision (April 15 expected)
12
Claims Verified
2
Claims Blocked
92%
Overall Confidence
Active Watchlist
Novo Nordisk
Escalation
📈
Last updated: 2 minutes ago
Pfizer
Stable
➡️
Last updated: 14 minutes ago
Moderna
De-escalation
📉
Last updated: 31 minutes ago
FDA CDER
Active
⚡
Last updated: 4 minutes ago
Eli Lilly
Escalation
📈
Last updated: 7 minutes ago
AbbVie
Stable
➡️
Last updated: 19 minutes ago
Hallucination Containment System
Confidence Breakdown
Confirmed (78%)
Inferred (15%)
Monitoring (5%)
Blocked (2%)
Verification Model Chain
Model A (Primary)
Model B (Verifier)
Model C (Tie-break)
Recent Blocked Claims
Claim: "Moderna Phase II results show 98% efficacy" — Blocked: No published data found, confidence below threshold
Claim: "FDA approved new biosimilar on March 30" — Blocked: Timeline inconsistency, approval date not verified
Alert Preferences
Email Alerts
Receive daily intelligence digest
Critical Alerts
Immediate notification for high-risk developments
Watchlist Changes
Updates when monitored entities change status
Anomaly Detection
Alerts for unusual activity patterns
Are You a Healthcare Professional? Join the FHIN Network
Help advance the intelligence ecosystem while building professional credentials and earning platform credits. Your insights are cited in our reports and directly shape what intelligence your peers see.
Contributor Benefits
Platform Credits — Earn credits toward your subscription
Impact Metrics — Track how your contributions influence the platform
Verified Badge — Display your professional credentials
Anonymous Option — Contribute under "Verified Anonymous Member" label
Data contributions are cited with your name and credentials unless you choose the anonymous option. Anonymous contributors are tracked internally but publicly labeled as "Verified Anonymous Member" to maintain trust in the intelligence network.
Join FHIN
We Want Your Feedback
This is a demo view only. Help us build the intelligence platform you need.